Brief: PCI Biotech: Successful Phase I fimaVacc Vaccination Proof Of Concept Study To Be Published In Frontiers In Immunology
23/11/2020 07:33
Nov 23 (Reuters) - PCI Biotech Holding ASA PCIB.OL :
* REG-PCI BIOTECH: SUCCESSFUL PHASE I FIMAVACC VACCINATION
PROOF
OF CONCEPT STUDY TO BE PUBLISHED IN FRONTIERS IN IMMUNOLOGY
* RESULTS PROVIDE PROOF-OF-CONCEPT BY DEMONSTRATING FIMAVACC
ENHANCES IMMUNE RESPONSES TO PEPTIDE AND PROTEIN BASED VACCINES
* STUDY SHOWS THAT FIMAVACC CAN BE SAFELY EMPLOYED IN
HUMANS.
Source text for Eikon: ID:nGNE2PbMTK
Further company coverage: PCIB.OL
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))
Recent news on PCI Biotech Holding ASA
See all newsBrief: Euronext Oslo Børs To Delist PCI Biotech Holding Shares
Brief: Euronext Oslo Børs Gets Application From PCI Biotech Holding For Delisting
Brief: PCI Biotech Holding Board Proposes Dissolution, Delisting
Brief: Oslo Bors: PCI Biotech Holding Is Placed In Recovery Box
Brief: PCI Biotech Says Co Initiates Process To Evaluate Opportunity For Structured Wind-Up Process